Patents by Inventor Vibeke Westphal Stennicke

Vibeke Westphal Stennicke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20170190775
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: December 8, 2016
    Publication date: July 6, 2017
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune SaIbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 9663568
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 30, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9550830
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: January 24, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF
    Publication number: 20160251434
    Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-?. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
    Type: Application
    Filed: February 6, 2015
    Publication date: September 1, 2016
    Inventors: Marco Colonna, Axel Bouchon, Rune Salbo, Charlotte Wiberg, Vibeke Westphal Stennicke, Anette Henriksen, Mette Dahl Andersen
  • Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)
    Publication number: 20150274825
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: February 26, 2015
    Publication date: October 1, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
    Patent number: 9000127
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 7, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Antibodies That Bind Peptidoglycan Recognition Protein 1
    Publication number: 20150018528
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 15, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joe Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)
    Publication number: 20130309239
    Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 21, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
  • Fusion Proteins That Bind Effector Lymphocytes And Target Cells
    Publication number: 20080299137
    Abstract: Novel fusion proteins that comprise a first portion that corresponds to an antibody-like protein that is specific for an activating receptor on an effector lymphocyte or a variant thereof and a second portion that corresponds to a portion of a cell membrane protein and that binds to a cell-associated target are provided, as are methods of producing such fusion proteins, uses and methods involving such fusion proteins, and compounds and compositions related to such fusion proteins.
    Type: Application
    Filed: October 27, 2006
    Publication date: December 4, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Ivan Svendsen, Vibeke Westphal Stennicke, Peter Andreas Nicolai Reumert Wagtmann
  • Transducer of MAS signalling
    Publication number: 20030219791
    Abstract: Two receptors of meiosis activating sterols designated SAM1a and SAM1b have been identified.
    Type: Application
    Filed: February 20, 2003
    Publication date: November 27, 2003
    Inventors: Vibeke Westphal Stennicke, Peder Lisby Norby, Christian Grondahl, Philip Wahl